Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2024 07:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
September 04, 2024 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
August 13, 2024 07:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing Additional dosing cohort (180mg Q8W) added to...
June 19, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
June 17, 2024 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
June 14, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
May 30, 2024 18:05 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
May 29, 2024 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
May 14, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
May 13, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in...